Clinical Trial Update: An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) [Phase 2]

View source ↗

Summary

This is an open-label extension study in Phase 2 evaluating the safety and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder, with or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SPT-300 (GlyphAllo) (GlyphAllo)

Snippet

Sponsor: Seaport Therapeutics | Conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | Phase 2 | Status: ENROLLING_BY_INVITATION